As questions swirl around lead drug, FibroGen (and AstraZeneca) find a new champion from Big Pharma

John Carroll

Editor & Founder

Two months after Enrique Conterno left his high-profile post as the head of Lilly Diabetes and Lilly USA, the 27-year pharma vet is back in the game — this time as the newly appointed CEO of a closely-watched biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

As questions swirl around lead drug, FibroGen (and AstraZeneca) find a new champion from Big Pharma

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Lilly scraps trials of Verzenio, Jardiance and a gene therapy from Prevail

Harmony Biosciences buys small epilepsy biotech for $35M, plus milestones

In one of JP Morgan's first biotech bets, Enlaza raises $100M for its permanently binding protein drugs

Real Chemistry debuts a one-stop dashboard for all things GLP-1

DNA sequencing firm PacBio to lay off workers and shutter San Diego office

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

As ques­tions swirl around lead drug, Fi­bro­Gen (and As­traZeneca) find a new cham­pi­on from Big Phar­ma

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Lil­ly scraps tri­als of Verzenio, Jar­diance and a gene ther­a­py from Pre­vail

Har­mo­ny Bio­sciences buys small epilep­sy biotech for $35M, plus mile­stones

In one of JP Mor­gan's first biotech bets, En­laza rais­es $100M for its per­ma­nent­ly bind­ing pro­tein drugs

Re­al Chem­istry de­buts a one-stop dash­board for all things GLP-1

DNA se­quenc­ing firm PacBio to lay off work­ers and shut­ter San Diego of­fice

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

As questions swirl around lead drug, FibroGen (and AstraZeneca) find a new champion from Big Pharma

Lilly scraps trials of Verzenio, Jardiance and a gene therapy from Prevail

Harmony Biosciences buys small epilepsy biotech for $35M, plus milestones

In one of JP Morgan's first biotech bets, Enlaza raises $100M for its permanently binding protein drugs

Real Chemistry debuts a one-stop dashboard for all things GLP-1

DNA sequencing firm PacBio to lay off workers and shutter San Diego office

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations